المؤلفون: Grivas, Petros, Mortazavi, Amir, Picus, Joel, Hahn, Noah M., Milowsky, Matthew I., Hart, Lowell L., Alva, Ajjai, Bellmunt, Joaquim, Pal, Sumanta K., Bambury, Richard M., O’donnell, Peter H., Gupta, Sumati, Guancial, Elizabeth A., Sonpavde, Guru P., Faltaos, Demiana, Potvin, Diane, Christensen, James G., Chao, Richard C., Rosenberg, Jonathan E.

مصطلحات موضوعية: urothelial carcinoma, CREB binding protein (CREBBP), E1A binding protein p300 (EP300), histone deacetylase, mocetinostat, Public Health, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

العلاقة: Grivas, Petros; Mortazavi, Amir; Picus, Joel; Hahn, Noah M.; Milowsky, Matthew I.; Hart, Lowell L.; Alva, Ajjai; Bellmunt, Joaquim; Pal, Sumanta K.; Bambury, Richard M.; O’donnell, Peter H.; Gupta, Sumati; Guancial, Elizabeth A.; Sonpavde, Guru P.; Faltaos, Demiana; Potvin, Diane; Christensen, James G.; Chao, Richard C.; Rosenberg, Jonathan E. (2019). "Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes." Cancer 125(4): 533-540.; http://hdl.handle.net/2027.42/147860Test; Cancer; Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004; 23: 4225 â 4231.; Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017; 71: 96 â 108.; Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumâ containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27: 4454 â 4461.; Choueiri TK, Ross RW, Jacobus S, et al. Doubleâ blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumâ pretreated metastatic urothelial cancer. J Clin Oncol. 2012; 30: 507 â 512.; Bellmunt J, de Wit R, Vaughn DJ, et al. KEYNOTEâ 045 Investigators. Pembrolizumab as secondâ line therapy for advanced urothelial carcinoma. N Engl J Med. 2017; 376: 1015 â 1026.; Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015; 20: 3898 â 3941.; Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell. 2014; 5: 265 â 296.; Poyet C, Jentsch B, Hermanns T, et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol. 2014; 14: 10.; Pinkerneil M, Hoffmann MJ, Deenen R, et al. Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms. Mol Cancer Ther. 2016; 15: 299 â 312.; Suraweera A, Oâ Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018; 8: 92.; Zhou N, Moradei O, Raeppel S, et al. Discovery of Nâ (2â aminophenyl)â 4â [(4â pyridinâ 3â ylpyrimidinâ 2â ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J Med Chem. 2008; 51: 4072 â 4075.; Batlevi CL, Crump M, Andreadis C, et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. Br J Haematol. 2017; 28: 2047 â 2049.; Blum KA, Advani A, Fernandez L, et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol. 2009; 147: 507 â 514.; Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkinâ s lymphoma: an openâ label, singleâ arm, phase 2 trial. Lancet Oncol. 2011; 12: 1222 â 1228.; Duex JE, Swain KE, Dancik GM, et al. Functional impact of chromatin remodeling gene mutations and predictive signature for therapeutic response in bladder cancer. Mol Cancer Res. 2018; 16: 69 â 77.; Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinumâ containing regimens. J Clin Oncol. 2010; 28: 1850 â 1855.; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507: 315 â 322.; Robertson AG, Kim J, Alâ Ahmadie H, et al. Comprehensive molecular characterization of muscleâ invasive bladder cancer. Cell. 2017; 171: 540 â 556.e525.; Wang F, Marshall CB, Ikura M. Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci. 2013; 70: 3989 â 4008.; Boumber Y, Younes A, Garciaâ Manero G. Mocetinostat (MGCD0103): a review of an isotypeâ specific histone deacetylase inhibitor. Expert Opin Investig Drugs. 2011; 20: 823 â 829.; Chan E, Chiorean EG, Oâ Dwyer PJ, et al. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. Cancer Chemother Pharmacol. 2018; 81: 355 â 364.; Schneider BJ, Kalemkerian GP, Bradley D, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs. 2012; 30: 249 â 257.; Munster PN, Marchion D, Thomas S, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009; 101: 1044 â 1050.; Cheung EM, Quinn DI, Tsaoâ Wei DD, et al. Phase II study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced transitional cell urothelial cancer after platinumâ based therapy. J Clin Oncol. 2008; 26 (suppl 15): 16058.; Pili R, Salumbides B, Zhao M, et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13â cis retinoic acid in patients with solid tumours. Br J Cancer. 2012; 106: 77 â 84.; Gupta S, Albertson DJ, Parnell T, et al. Clinical and translational investigation of panâ HDAC inhibition in advanced urothelial carcinoma. J Clin Oncol. 2017; 35 (suppl 6): 379.; Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large Bâ cell lymphoma. Blood. 2016; 128: 185 â 194.; Falkenberg KJ, Gould CM, Johnstone RW, Simpson KJ. Genomeâ wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat. Sci Data. 2014; 1: 140017.; Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC inhibition upregulates PDâ 1 ligands in melanoma and augments immunotherapy with PDâ 1 blockade. Cancer Immunol Res. 2015; 3: 1375 â 1385.

الإتاحة: https://doi.org/10.1002/cncr.31817Test
http://hdl.handle.net/2027.42/147860Test

المؤلفون: Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon, Harshman, Lauren C, Bellmunt, Joaquim, de Giorgi, Ugo, Sternberg, Cora N, Cerbone, Linda, Ladoire, Sylvain, Yu, Yu-Ning, Yu, Evan y, Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N, Pal, Sumanta K, Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W, Milowsky, Matthew I, Theodore, Christine, Berthold, Dominik R, Daugaard, Gedske, Sridhar, Srikala S, Powles, Thomas, Rosenberg, Jonathan E, Galsky, Matthew D, Mariani, Luigi

المساهمون: IRCCS Istituto Nazionale dei Tumori Milano, UAB Comprehensive Cancer Center UAB Comprehensive Cancer Center Birmingham, AL, USA, University of Alabama at Birmingham Birmingham (UAB), National and Kapodistrian University of Athens (NKUA), University of Southampton, Dana-Farber Cancer Institute Boston, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, San Camillo Forlanini Hospital Rome, Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon (UNICANCER/CRLCC-CGFL), UNICANCER, Fox Chase Cancer Center, University of Washington Seattle, Guy's and St Thomas' Hospital London, Heinrich Heine Universität Düsseldorf = Heinrich Heine University Düsseldorf, Stanford School of Medicine Stanford, Stanford Medicine, Stanford University-Stanford University, Karmanos Cancer Institute, City of Hope Comprehensive Cancer Center Duarte, School of Medicine University of Utah, Salt Lake City, University of Utah, University of Michigan Ann Arbor, University of Michigan System, Rabin Medical Center - Beilinson and Hasharon Hospitals Petach-Tikva, Israel, Medical University of South Carolina Charleston (MUSC), Vall d'Hebron Institute of Oncology Barcelone (VHIO), Vall d'Hebron University Hospital Barcelona, Service d'Oncologie Médicale, Service d'Oncologie Médicale, Hôpital Foch, Suresnes, Dept of Oncology, Rigshospitalet Copenhagen, Copenhagen University Hospital-Copenhagen University Hospital, Barts & The London School of Medicine, Memorial Sloane Kettering Cancer Center New York, Icahn School of Medicine at Mount Sinai New York (MSSM)

المصدر: ISSN: 0302-2838.

مصطلحات موضوعية: Nomogram, Overall survival, Platinum chemotherapy, Prognosis, Urothelial carcinoma, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27726966; hal-01556096; https://u-bourgogne.hal.science/hal-01556096Test; PUBMED: 27726966; PUBMEDCENTRAL: PMC5576985

الإتاحة: https://doi.org/10.1016/j.eururo.2016.09.042Test
https://u-bourgogne.hal.science/hal-01556096Test

المؤلفون: Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon J., Harshman, Lauren C., Bellmunt, Joaquim, De Giorgi, Ugo, Sternberg, Cora N., Cerbone, Linda, Ladoire, Sylvain, Wong, Yu-Ning, Yu, Evan Y., Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N., Pal, Sumanta K., Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W., Milowsky, Matthew I., Theodore, Christine, Berthold, Dominik R., Daugaard, Gedske, Sridhar, Srikala S., Powles, Thomas, Rosenberg, Jonathan E., Galsky, Matthew D., Mariani, Luigi

المصدر: European Urology, 71(2)

مصطلحات موضوعية: Platinum chemotherapy, Overall survival, Prognosis, Urothelial carcinoma, Nomogram

العلاقة: https://doi.org/10.17615/3th6-zf65Test; https://cdr.lib.unc.edu/downloads/bg257m072?file=thumbnailTest; https://cdr.lib.unc.edu/downloads/bg257m072Test

الإتاحة: https://doi.org/10.17615/3th6-zf65Test
https://cdr.lib.unc.edu/downloads/bg257m072?file=thumbnailTest
https://cdr.lib.unc.edu/downloads/bg257m072Test

المؤلفون: Necchi, Andrea, Sonpavde, Guru, Lo Vullo, Salvatore, Giardiello, Daniele, Bamias, Aristotelis, Crabb, Simon, Harshman, Lauren C, Bellmunt, Joaquim, De Giorgi, Ugo, Sternberg, Cora N, Cerbone, Linda, Ladoire, Sylvain, Yu, Yu-Ning, Yu, Evan Y, Chowdhury, Simon, Niegisch, Gunter, Srinivas, Sandy, Vaishampayan, Ulka N, Pal, Sumanta K, Agarwal, Neeraj, Alva, Ajjai, Baniel, Jack, Golshayan, Ali-Reza, Morales-Barrera, Rafael, Bowles, Daniel W, Milowsky, Matthew I, Theodore, Christine, Berthold, Dominik R, Daugaard, Gedske, Sridhar, Srikala S, Powles, Thomas, Rosenberg, Jonathan E, Galsky, Matthew D, Mariani, Luigi

المساهمون: Fondazione IRCCS Istituto Nazionale dei Tumori, UAB Comprehensive Cancer Center UAB Comprehensive Cancer Center Birmingham, AL, USA, University of Alabama at Birmingham Birmingham (UAB), National and Kapodistrian University of Athens (NKUA), University of Southampton, Dana-Farber Cancer Institute Boston, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), San Camillo Forlanini Hospital Rome, Centre Régional de Lutte contre le cancer Georges-François Leclerc Dijon (UNICANCER/CRLCC-CGFL), UNICANCER, Fox Chase Cancer Center, University of Washington Seattle, Guy's and St Thomas' Hospital London, Heinrich Heine Universität Düsseldorf = Heinrich Heine University Düsseldorf, Stanford School of Medicine Stanford, Stanford Medicine, Stanford University-Stanford University, Karmanos Cancer Institute, City of Hope Comprehensive Cancer Center Duarte, University of Utah School of Medicine Salt Lake City, University of Michigan Ann Arbor, University of Michigan System, Rabin Medical Center - Beilinson and Hasharon Hospitals Petach-Tikva, Israel, Medical University of South Carolina Charleston (MUSC), Vall d'Hebron Institute of Oncology Barcelone (VHIO), Vall d'Hebron University Hospital Barcelona, Service d'Oncologie Médicale, Service d'Oncologie Médicale, Hôpital Foch, Suresnes, Dept of Oncology, Rigshospitalet Copenhagen, Copenhagen University Hospital-Copenhagen University Hospital, Barts & The London School of Medicine, Memorial Sloane Kettering Cancer Center New York, Icahn School of Medicine at Mount Sinai New York (MSSM)

المصدر: ISSN: 0302-2838.

مصطلحات موضوعية: Nomogram, Overall survival, Platinum chemotherapy, Prognosis, Urothelial carcinoma, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/27726966; hal-01556096; https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01556096Test; PUBMED: 27726966

الإتاحة: https://doi.org/10.1016/j.eururo.2016.09.042Test
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01556096Test